Niessner A - Search Results

1

Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha.

Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Niessner A, et al. Circulation. 2006 Dec 5;114(23):2482-9. doi: 10.1161/CIRCULATIONAHA.106.642801. Epub 2006 Nov 20. Circulation. 2006. PMID: 17116765

2

Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque.

Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Niessner A, et al. Circulation. 2007 Oct 30;116(18):2043-52. doi: 10.1161/CIRCULATIONAHA.107.697789. Epub 2007 Oct 15. Circulation. 2007. PMID: 17938289

3

TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque.

Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. Sato K, et al. Among authors: niessner a. J Exp Med. 2006 Jan 23;203(1):239-50. doi: 10.1084/jem.20051062. Epub 2006 Jan 17. J Exp Med. 2006. PMID: 16418392 Free PMC article.

4

Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque.

Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. Zhang X, et al. Among authors: niessner a. Circ Res. 2006 Mar 3;98(4):524-31. doi: 10.1161/01.RES.0000204452.46568.57. Epub 2006 Jan 19. Circ Res. 2006. PMID: 16424368

5

Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations.

Niessner A, Goronzy JJ, Weyand CM. Niessner A, et al. Curr Pharm Des. 2007;13(36):3701-10. doi: 10.2174/138161207783018626. Curr Pharm Des. 2007. PMID: 18220809 Review.

6

Dendritic cells in atherosclerotic disease.

Niessner A, Weyand CM. Niessner A, et al. Clin Immunol. 2010 Jan;134(1):25-32. doi: 10.1016/j.clim.2009.05.006. Epub 2009 Jun 10. Clin Immunol. 2010. PMID: 19520615 Free PMC article. Review.

7

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.

Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J. Niessner A, et al. Atherosclerosis. 2006 Dec;189(2):408-13. doi: 10.1016/j.atherosclerosis.2005.12.022. Epub 2006 Jan 26. Atherosclerosis. 2006. PMID: 16443229 Clinical Trial.

8

Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation.

Niessner A, Marculescu R, Haschemi A, Endler G, Zorn G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K. Niessner A, et al. Thromb Haemost. 2005 May;93(5):949-54. doi: 10.1160/TH04-11-0735. Thromb Haemost. 2005. PMID: 15886814

9

Inflammation and cardiac outcome.

Hohensinner PJ, Niessner A, Huber K, Weyand CM, Wojta J. Hohensinner PJ, et al. Among authors: niessner a. Curr Opin Infect Dis. 2011 Jun;24(3):259-64. doi: 10.1097/QCO.0b013e328344f50f. Curr Opin Infect Dis. 2011. PMID: 21378564 Free PMC article. Review.

10

Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis.

Niessner A, Marculescu R, Kvakan H, Haschemi A, Endler G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K. Niessner A, et al. Thromb Haemost. 2005 Dec;94(6):1251-6. Thromb Haemost. 2005. PMID: 16411402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters